Fibromyalgia

The short version

●Fibromyalgia is a chronic disorder of widespread musculoskeletal pain accompanied by fatigue, unrefreshing sleep, and cognitive difficulty ("fibro fog"): a prototype of central sensitization, where the nervous system amplifies pain.
●It is not inflammatory or degenerative joint disease and does not show up on standard imaging or labs; it is a disorder of pain processing, which is why ordinary painkillers help little.
●First-line treatment is multimodal: graded exercise, sleep and stress management, pain-focused therapy (CBT), and centrally-acting medications (duloxetine, milnacipran, pregabalin, low-dose amitriptyline).
●Depression and anxiety are very common in fibromyalgia and share its neurobiology of central sensitization; treating mood is part of treating the pain.
●Ketamine targets central sensitization through NMDA-receptor antagonism; the fibromyalgia-specific trial evidence is limited and mostly short-lived, so it is not a standard treatment.
●Ketamine is most reasonable for refractory fibromyalgia with co-occurring treatment-resistant depression, as part of a comprehensive plan, not as a standalone cure.

Clinical definition

Fibromyalgia is a chronic central sensitization syndrome defined by widespread pain present for at least three months, together with fatigue, waking unrefreshed, and cognitive symptoms, after other conditions that could explain the symptoms have been considered. Modern diagnostic criteria use a widespread pain index and symptom severity scale rather than the older tender-point exam. The core abnormality is in how the central nervous system processes sensory input (pain amplification, reduced descending inhibition, and heightened responsiveness) rather than damage or inflammation in the muscles and joints themselves. This is why standard imaging and inflammatory labs are normal, and why nonsteroidal anti-inflammatories and opioids are largely ineffective. Fibromyalgia frequently co-occurs with depression, anxiety, irritable bowel syndrome, headaches, and other centralized pain conditions, reflecting shared central mechanisms.

How it differs from related conditions

vs. Chronic pain

Fibromyalgia is a specific, well-defined chronic primary pain syndrome; "chronic pain" is the broader umbrella that also includes neuropathic and structural pain with different treatments.

vs. Chronic fatigue syndrome (ME/CFS)

Overlaps substantially (fatigue, cognitive symptoms, unrefreshing sleep) and the two often co-occur; CFS centers on post-exertional malaise and profound fatigue rather than widespread pain.

vs. Rheumatoid arthritis / autoimmune disease

Inflammatory joint diseases show objective inflammation, joint damage, and abnormal labs/imaging; fibromyalgia does not, though it can coexist with them and amplify their pain.

vs. Major depressive disorder

Depression and fibromyalgia share central neurobiology and frequently co-occur; fibromyalgia is distinguished by its widespread pain and the central sensitization picture, but mood must be screened and treated.

First-line treatments

Graded aerobic and resistance exercise

The single best-supported intervention; improves pain, function, and fatigue despite initially feeling counterintuitive. Started low and increased slowly to avoid flares.

Centrally-acting medications

Duloxetine and milnacipran (SNRIs), pregabalin (FDA-approved for fibromyalgia), and low-dose amitriptyline target the central pain processing; NSAIDs and opioids are largely ineffective.

Cognitive-behavioral therapy and stress management

Reduces pain interference, improves coping and sleep, and addresses the stress-pain feedback loop; among the most durable components.

Sleep optimization

Unrefreshing sleep is core to fibromyalgia and amplifies pain; targeted sleep treatment (including CBT-I) is a high-yield part of care.

Evidence-based therapy guides

CBT All therapy guides

When standard treatments fail

When exercise, the approved centrally-acting medications, and CBT do not adequately control symptoms, the path is to confirm the components were genuinely tried (exercise and CBT are frequently under-dosed or abandoned early), rotate or combine the central agents, aggressively treat sleep and any comorbid depression or anxiety, and screen for co-occurring conditions that may be driving the picture. Because fibromyalgia is fundamentally a central sensitization disorder, refractory cases (particularly with co-occurring treatment-resistant depression) are where glutamatergic interventions such as ketamine are considered, within a comprehensive plan rather than as a replacement for it.

Where ketamine fits

Ketamine is mechanistically attractive for fibromyalgia because it blocks NMDA receptors central to the pain amplification (central sensitization) that defines the condition. In practice, the fibromyalgia-specific controlled evidence is limited and the analgesic effects observed have generally been modest and short-lived, so ketamine is not an established fibromyalgia treatment and should not be presented as one. Its more defensible role is for refractory fibromyalgia that co-occurs with treatment-resistant depression (an extremely common pairing given the shared central neurobiology) where ketamine can target the mood disorder with strong evidence and may transiently dampen the centralized pain. It is delivered within a comprehensive plan that keeps exercise, sleep, and psychological care central; it does not replace them. Patients seeking ketamine as a primary fibromyalgia cure should understand the evidence is preliminary.

Where this fits with Tovani

Tovani treats fibromyalgia primarily when it co-occurs with treatment-resistant depression or anxiety, which is the situation with the clearest rationale and evidence. Eligibility screening captures symptom severity, prior treatments, sleep, and mood, and patients are encouraged to maintain the foundations (graded exercise, sleep treatment, and CBT) alongside ketamine. Tovani is candid that the fibromyalgia-specific ketamine evidence is preliminary; patients looking for a standalone fibromyalgia cure are counseled accordingly rather than offered ketamine on that basis.

Check eligibility How Tovani treats Fibromyalgia Find treatment options The science behind ketamine

Frequently asked

Can ketamine cure my fibromyalgia?

No, and anyone promising that is overstating the evidence. The fibromyalgia-specific ketamine research is limited and the pain relief seen has generally been modest and short-lived. Ketamine has a clearer role when fibromyalgia coexists with treatment-resistant depression, as part of a broader plan.

Why don't normal painkillers work for fibromyalgia?

Because fibromyalgia is a disorder of how the nervous system processes pain (central sensitization), not tissue damage or inflammation. NSAIDs and opioids target tissue-level pain and largely miss the central mechanism, which is why centrally-acting drugs and exercise work better.

Is exercise really going to help when I hurt so much?

Counterintuitively, graded exercise is the best-supported treatment for fibromyalgia: improving pain, fatigue, and function over time. The key is starting very low and increasing slowly to avoid flares, ideally with guidance.

I have fibromyalgia and depression: is ketamine an option?

That combination is where ketamine makes the most sense. The two share central neurobiology and frequently co-occur; ketamine targets the treatment-resistant depression with strong evidence and may help the centralized pain. Tovani screens for this pairing.

References

Clauw DJ 2014, JAMA — Clinical review of fibromyalgia as a central sensitization disorder, including diagnosis and the evidence base for exercise, CBT, and centrally-acting medications. (PMID 24737367)
Cohen SP et al. 2018, Regional Anesthesia and Pain Medicine — Consensus guidelines on intravenous ketamine for chronic pain, addressing centralized pain states and the limits of the evidence. (PMID 29870458)
Murrough JW et al. 2013, American Journal of Psychiatry — Ketamine RCT in treatment-resistant depression: the comorbidity that gives ketamine its clearest role in fibromyalgia. (PMID 23982301)

Last reviewed by Dr. Ben Soffer, DO on May 31, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.